Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity? | Zendy

Kati Choi | Zendy; Hamzah AbuSbeih | Zendy; Rashmi Samdani | Zendy; Graciela Nogueras González | Zendy; Gottumukkala S. Raju | Zendy; David M. Richards | Zendy; Jianjun Gao | Zendy; Sumit K. Subudhi | Zendy; John Stroehlein | Zendy; Yinghong Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?

Author(s) -

Kati Choi,

Hamzah AbuSbeih,

Rashmi Samdani,

Graciela Nogueras González,

Gottumukkala S. Raju,

David M. Richards,

Jianjun Gao,

Sumit K. Subudhi,

John Stroehlein,

Yinghong Wang

Publication year - 2018

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1093/ibd/izy240

Subject(s) - medicine , colitis , cancer , gastroenterology , diarrhea , colorectal cancer , population , cohort , retrospective cohort study , environmental health

Microscopic colitis (MC) has been described as 1 pattern of injury in immune checkpoint inhibitor (ICPI)-induced colitis. The main objective of this study was to characterize ICPI-induced MC by exploring the differences in risk factors, colitis treatments, endoscopic features, and clinical outcomes between cancer and noncancer patients with MC with and without exposure to ICPIs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research